Since SFRP4 expression has been shown to be lost in a large majority of ovarian cancer patients [18], this raises the possibility that modulation of Wnt signalling through SFRP4 or other upstream Wnt pathway members may represent a new avenue for targeted therapy in ovarian cancer. The gene discussed is SFRP4; the disease is ovarian carcinoma.